Valuation: Fifty 1 Labs, Inc.

Market Cap 281K 251K 234K 213K 402K 27.24M 403K 2.81M 1.1M 13.89M 1.06M 1.03M 44.57M P/E 2009
-0.05x
P/E 2010 -0.01x
Enterprise Value 12.55M 11.21M 10.43M 9.49M 17.91M 1.22B 17.99M 126M 49.19M 619M 47.14M 46.11M 1.99B EV / Sales 2009
1.86x
EV / Sales 2010 2.41x
Free-Float
47.75%
Yield 2009 *
-
Yield 2010 -
1 week-33.33%
Current month-20.00%
3 months-77.78%
6 months-50.00%
Current year-60.00%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0
1 year 0
Extreme 0.0001
0
3 years 0
Extreme 0.0001
0.05
5 years 0
Extreme 0.0001
0.2
10 years 0
Extreme 0.0001
0.23
Manager TitleAgeSince
Chief Executive Officer 47 -
President - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 49 2025-04-29
Chairman - 2023-07-11
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-33.33%-90.48%-98.89% 237K
-2.59%-5.70%+39.83%+82.45% 70.61B
+3.23%-10.67%+4.87%+55.97% 51.01B
+1.56%+1.17%+5.15%+33.38% 48.1B
+0.39%+0.65%+28.02%+30.24% 42.78B
+0.87%-8.17%+298.53%+645.03% 40.67B
+1.24%-1.01%+5.56%+105.14% 40.3B
-2.13%-1.64%+7.51%+50.31% 30.59B
-0.46%-1.28%+31.47%+19.93% 28.16B
+5.32%+0.06%-7.20%-11.30% 24.36B
Average +0.74%-5.72%+32.33%+91.23% 37.66B
Weighted average by Cap. +0.56%-2.94%+47.30%+116.51%

Financials

2009 2010
Net sales 5.41M 4.83M 4.5M 4.09M 7.72M 524M 7.75M 54.11M 21.2M 267M 20.32M 19.88M 857M 5.11M 4.56M 4.24M 3.86M 7.29M 494M 7.32M 51.06M 20.01M 252M 19.18M 18.76M 809M
Net income -2.23M -1.99M -1.85M -1.69M -3.18M -216M -3.2M -22.31M -8.74M -110M -8.38M -8.2M -353M -1.89M -1.69M -1.57M -1.43M -2.7M -183M -2.71M -18.94M -7.42M -93.47M -7.11M -6.96M -300M
Net Debt 9.96M 8.89M 8.27M 7.52M 14.21M 964M 14.27M 99.55M 39.01M 491M 37.39M 36.57M 1.58B 12.27M 10.96M 10.2M 9.27M 17.51M 1.19B 17.59M 123M 48.08M 606M 46.09M 45.08M 1.94B
Logo Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and life sciences company. The Company focuses on peptide products, peptide discovery, AI-enabled research, and clinical development. It also focuses on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness. It owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health. It has acquired a musculoskeletal recovery product line. The product line includes five key product concepts designed to support the Company's peptide and musculoskeletal health markets. The portfolio includes natural health products focused on connective tissue recovery, inflammation support, post-surgical recovery nutrition, joint and cartilage support, and an investigational BPC-157-focused research platform.
Employees
2
Date Price Change Volume
26-10-09 US$0.000200 0.00% 165,500
26-10-08 US$0.000200 0.00% 3,000,001
26-10-07 US$0.000200 0.00% 376,513
26-10-06 US$0.000200 0.00% 19,856,562
26-10-05 US$0.000200 -33.33% 2,655,000
  1. Stock Market
  2. Stocks
  3. FITY Stock